Form 4: Beam Therapeutics Chief Legal Officer Sells Shares to Cover Tax Obligations

Christine Bellon, Chief Legal Officer of Beam Therapeutics, sold 1,241 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Christine Bellon, the Chief Legal Officer of Beam Therapeutics, sold 1,241 shares of common stock on January 2, 2025.
• The sale was executed to cover tax withholding obligations arising from the vesting of restricted stock units.
• The shares were sold at a weighted average price of $24.68, with individual transactions ranging from $24.21 to $25.02.
• The sale was conducted automatically under a pre-arranged Rule 10b5-1 trading plan adopted on May 19, 2023.
• Following the transaction, Ms. Bellon directly owns 102,968 shares of Beam Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction for tax purposes, which is neither positive nor negative for the company's overall performance. The use of a 10b5-1 plan indicates a planned and transparent approach to stock sales.

Industry Context

This is a routine transaction for corporate insiders to manage their tax obligations related to equity compensation. It is common for executives to use Rule 10b5-1 trading plans to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate executives to manage stock sales and avoid insider trading accusations, aligning with industry standards.
• The sale of shares to cover tax obligations is a typical event following the vesting of restricted stock units, which is a standard form of executive compensation across the industry.
• The price range of $24.21 to $25.02 is within the expected range for a stock sale of this type, and the weighted average price of $24.68 is a standard metric for reporting such transactions.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is unlikely to be significant given the relatively small number of shares sold and the pre-planned nature of the transaction.
• The transaction is transparent and in compliance with regulations, which should reassure shareholders.

Key Dates

Keywords

Beam Therapeutics, insider trading, stock sale, Rule 10b5-1, Christine Bellon, tax obligations, equity compensation